BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 24690476)

  • 41. Adjuvant therapy in stage III endometrial cancer: treatment outcomes and survival. a single-institution retrospective study.
    Kuku S; Williams M; McCormack M
    Int J Gynecol Cancer; 2013 Jul; 23(6):1056-64. PubMed ID: 23765205
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Long-term oncological outcomes after laparoscopic versus abdominal radical hysterectomy in stage I a2- II a2 cervical cancer: a matched cohort study].
    Wang W; Shang C; Huang J; Chen S; Shen H; Yao S
    Zhonghua Fu Chan Ke Za Zhi; 2015 Dec; 50(12):894-901. PubMed ID: 26887872
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognosis for endometrial cancer patients treated with systematic pelvic and para-aortic lymphadenectomy followed by platinum-based chemotherapy.
    Sueoka K; Umayahara K; Abe A; Usami T; Yamamoto A; Nomura H; Matoda M; Okamoto S; Omatsu K; Kondo E; Kato K; Takeshima N
    Int J Gynecol Cancer; 2015 Jan; 25(1):81-6. PubMed ID: 25347094
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment outcomes of patients with stage II pure endometrioid-type endometrial cancer: a Taiwanese Gynecologic Oncology Group (TGOG-2006) retrospective cohort study.
    Fu HC; Chen JR; Chen MY; Hsu KF; Cheng WF; Chiang AJ; Ke YM; Chen YC; Chang YY; Huang CY; Kang CY; Kan YY; Hsiao SM; Yen MS
    J Gynecol Oncol; 2018 Sep; 29(5):e76. PubMed ID: 30022636
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Survival impact based on the thoroughness of pelvic lymphadenectomy in intermediate- or high-risk groups of endometrioid-type endometrial cancer: A multi-center retrospective cohort analysis.
    Kim TH; Kim HS; Kim TJ; Chang SJ; Kim DY; Ryu SY; Kim BG; Kim YT; Bae DS; Ryu HS; Nam JH
    Gynecol Oncol; 2016 Jun; 141(3):440-446. PubMed ID: 27020700
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A novel model to predict cancer-specific survival in patients with early-stage uterine papillary serous carcinoma (UPSC).
    Chen L; Liu X; Li M; Wang S; Zhou H; Liu L; Cheng X
    Cancer Med; 2020 Feb; 9(3):988-998. PubMed ID: 31846222
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recurrence Risk Stratification for Women With FIGO Stage I Uterine Endometrioid Carcinoma Who Underwent Surgical Lymph Node Evaluation.
    Ghanem AI; Bhatnagar A; Elshaikh M; Hijaz M; Elshaikh MA
    Am J Clin Oncol; 2023 Dec; 46(12):537-542. PubMed ID: 37679878
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of surgical approach on risk of recurrence after vaginal brachytherapy in early-stage high-intermediate risk endometrial cancer.
    Philp L; Tannenbaum S; Haber H; Saini A; Laurent JS; James K; Feltmate CM; Russo AL; Growdon WB
    Gynecol Oncol; 2021 Feb; 160(2):389-395. PubMed ID: 33358198
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Synchronous primary cancers of the endometrium and ovary: review of 43 cases].
    Ma SK; Zhang HT; Sun YC; Wu LY
    Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):690-4. PubMed ID: 19173912
    [TBL] [Abstract][Full Text] [Related]  

  • 50. What Is the Optimal Adjuvant Treatment Sequence for Node-Positive Endometrial Cancer? Results of a National Cancer Database Analysis.
    Modh A; Ghanem AI; Burmeister C; Hanna RK; Elshaikh MA
    Int J Gynecol Cancer; 2018 Feb; 28(2):248-253. PubMed ID: 29240603
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nomogram with potential clinical use to predict lymph node metastasis in endometrial cancer patients diagnosed incidentally by postoperative pathological assessment.
    Taşkın S; Şükür YE; Varlı B; Koyuncu K; Seval MM; Ateş C; Yüksel S; Güngör M; Ortaç F
    Arch Gynecol Obstet; 2017 Oct; 296(4):803-809. PubMed ID: 28762064
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Stages I to II WHO 2003-defined low-grade endometrial stromal sarcoma: how much primary therapy is needed and how little is enough?
    Feng W; Hua K; Malpica A; Zhou X; Baak JP
    Int J Gynecol Cancer; 2013 Mar; 23(3):488-93. PubMed ID: 23435438
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Development and validation of a comprehensive clinical risk-scoring model for prediction of overall survival in patients with endometrioid endometrial carcinoma.
    AlHilli MM; Rybicki L; Carr C; Yao M; Amarnath S; Vargas R; Debernardo R; Michener C; Rose PG
    Gynecol Oncol; 2021 Dec; 163(3):511-516. PubMed ID: 34607712
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Redefining stage I endometrial cancer: incorporating histology, a binary grading system, myometrial invasion, and lymph node assessment.
    Barlin JN; Soslow RA; Lutz M; Zhou QC; St Clair CM; Leitao MM; Iasonos A; Hensley ML; Barakat RR; Matias-Guiu X; Abu-Rustum NR
    Int J Gynecol Cancer; 2013 Nov; 23(9):1620-8. PubMed ID: 24126219
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Is lymphadenectomy a prognostic marker in endometrioid adenocarcinoma of the human endometrium?
    Bassarak N; Blankenstein T; Brüning A; Dian D; Bergauer F; Friese K; Mylonas I
    BMC Cancer; 2010 May; 10():224. PubMed ID: 20492712
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Type II endometrial cancer in Hispanic women: tumor characteristics, treatment and survival compared to non-Hispanic white women.
    Mahdi H; Hou H; Kowk LL; Moslemi-Kebria M; Michener C
    Gynecol Oncol; 2014 Jun; 133(3):512-7. PubMed ID: 24674830
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Are uterine risk factors more important than nodal status in predicting survival in endometrial cancer?
    Kwon JS; Qiu F; Saskin R; Carey MS
    Obstet Gynecol; 2009 Oct; 114(4):736-743. PubMed ID: 19888029
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Improved survival endpoints with adjuvant radiation treatment in patients with high-risk early-stage endometrial carcinoma.
    Elshaikh MA; Vance S; Suri JS; Mahan M; Munkarah A
    Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):351-6. PubMed ID: 24411608
    [TBL] [Abstract][Full Text] [Related]  

  • 59. FIGO stage IIIC endometrial carcinoma: prognostic factors and outcomes.
    Hoekstra AV; Kim RJ; Small W; Rademaker AW; Helenowski IB; Singh DK; Schink JC; Lurain JR
    Gynecol Oncol; 2009 Aug; 114(2):273-8. PubMed ID: 19428094
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Association of Pelvic and Para-Aortic Lymphadenectomy With Survival in Stage I Endometrioid Endometrial Cancer: Matched Cohort Analyses From the National Cancer Database.
    Seagle BL; Kocherginsky M; Shahabi S
    JCO Clin Cancer Inform; 2017 Nov; 1():1-14. PubMed ID: 30657385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.